XOMA Royalty Corporation
XOMAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeXOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. Valued at $710.2M, XOMA is a small-cap name in its sector. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates.
Market Cap
$710.2M
Beta
0.86
P/E (TTM)
25.59
P/E (Fwd)
18.77
EPS (TTM)
$1.57
EPS (Fwd)
$2.14
ROE
34.2%
ROA
1.3%
Cash
$86.1M
Total Debt
$124.7M
Free CF
-$13.1M
52W Change
53.0%
Annual Financials
Cash vs Debt
The company holds $86.1M in cash, though total debt stands at $124.7M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$13.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 34.2%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.3% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $6.0M (2022) to $11.7M (2025), reflecting a 93% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence XOMA Royalty Corporation's trajectory.